Cereno Scientific obtains first patent for drug candidate HDAC inhibitor CS014 in development for thrombosis prevention treatment
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that drug candidate CS014, a novel HDAC inhibitor, has obtained an issued patent in the UK. This is the drug candidate’s first patent that strengthens the positioning of CS014, which is currently in the preparatory stages of a Phase I study and being developed to effectively prevent thrombosis without increasing the risk of bleeding.
“This is a significant milestone for our CS014 project. We have with this started to build strong intellectual property rights around CS014, which will favorably support the drug candidate’s position toward key external stakeholders. We are currently pursuing the next step of CS014’s development with an upcoming submission of a clinical trial application to evaluate CS014’s safety and tolerability in a first-in-man study to be initiated during Q2 this year. Thrombosis is a major global health concern as it is a leading cause of death worldwide. Despite this, there is currently no effective drug treatment without serious side effects, of which fatal bleedings caused by drug therapy are the most serious. Cereno’s innovative drug candidate CS014 has demonstrated with a novel mode of action in animal models, known to be highly translatable to humans, to be able to effectively prevent thrombosis without increasing the risk of bleeding. Thus, CS014 has the potential to fulfill a significant unmet clinical need,” said Sten R. Sörensen, CEO at Cereno Scientific.
The patent is titled “Novel compounds and methods of use thereof.” The patent number assigned is GB2613900 B, and the patent will be valid through 2042.
The investigational drug CS014 is a histone deacetylase inhibitor (HDACi) in development as a treatment for arterial and venous thrombosis prevention. This innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. The drug candidate CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding. In preclinical studies, CS014 demonstrates inhibition of clot formation following platelet injury by significantly attenuating platelet activation and reducing fibrin formation at the injury site. CS014 potentially offers a significantly lower risk of bleeding compared to other novel oral anticoagulants, as validated in preclinical studies. The preclinical safety program for drug candidate CS014 was successfully completed at the end of 2023. CS014’s safety and tolerability will be further assessed in the Phase I study planned to be initiated in H1 2024.
For further information, please contact:
Tove Bergenholt, Director IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 732-366 246
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q2 2024. After requests by investigators in the Phase II study, a “compassionate use” application for CS1 is currently being pursued. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.